Tesamorelin
Tesamorelin (Egrifta)
GHRH analog targeting visceral fat
Fat LossAnti-Aging ★ 75 FDA Approved
Half-life
~26-38 min, but effects sustained
Cycle
16-26 weeks on, 4-8 weeks off
Storage
Lyophilized: refrigerated. Reconstituted: 2-8°C, 7 days.
Research
FDA approved 2010 for HIV-associated lipodystrophy
About
FDA-approved GHRH analog, used in HIV lipodystrophy. Highly effective for visceral fat reduction.
Mechanism
GHRH analog with a longer half-life, stimulating the GH/IGF-1 axis.
Dosage
1 mg
1x per day before sleep
0102030405060708090100
Draw to 50 units on a U-100 insulin syringe
5 mg · 2.5 mL BAC
Route
SubQ
Duration
12 weeks
When to take: On an empty stomach before sleep (30-60 min prior).
Reconstitution
Vial size (mg): 5 mg · BAC water (mL): 2.5 mL · Concentration: 2 mg/mL
Fragile — always store refrigerated after reconstitution.
Benefits
- Significant visceral fat reduction
- Improved lipid profile
- Increased IGF-1
- Muscle building
- Improved energy
Side effects
- Facial flushing
- Tingling
- Fluid retention
- Joint pain
- Rare: elevated blood glucose
Gender notes
Same dose. Best for middle-age belly fat.
Cautions
- Pituitary disease
- Active cancer
- Pregnancy
- Diabetes (requires monitoring)
Research
- Falutz J et al: Tesamorelin reduces visceral fat in HIV
New England Journal of Medicine · 2007
26-week study, 15% reduction in visceral fat vs placebo.
- Stanley TL et al: Tesamorelin and NAFLD
The Lancet HIV · 2019
Tesamorelin reduces fatty liver independent of HIV status.